## SPECIALTY GUIDELINE MANAGEMENT

# POMBILITI (cipaglucosidase alfa-atga)

### **POLICY**

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### **FDA-Approved Indication**

Pombiliti is indicated, in combination with Opfolda, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing greater than or equal to 40 kg and who are not improving on their current enzyme replacement therapy (ERT).

All other indications are considered experimental/investigational and not medically necessary.

#### **II. DOCUMENTATION**

Submission of the following information is necessary to initiate the prior authorization review:

- A. Initial requests: acid alpha-glucosidase enzyme assay or genetic testing results supporting diagnosis.
- B. Continuation requests: chart notes documenting a positive response to therapy (e.g., improvement, stabilization, or slowing of disease progression for motor function, walking capacity, respiratory function, muscle strength).

### III. CRITERIA FOR INITIAL APPROVAL

## **Late-onset Pompe disease**

Authorization of 12 months may be granted for treatment of late-onset Pompe disease when all of the following criteria are met:

- A. Member is 18 years of age or older.
- B. Member weighs greater than or equal to 40 kg.
- C. Diagnosis was confirmed by enzyme assay demonstrating a deficiency of acid alpha-glucosidase enzyme activity or by genetic testing.
- D. Member is not improving on current enzyme replacement therapy (ERT) (e.g., Lumizyme, Nexviazyme).
- E. The requested medication will be taken in combination with Opfolda (miglustat).

#### IV. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in Section III when both of the following criteria are met:

- A. Member is responding to therapy (e.g., improvement, stabilization, or slowing of disease progression for motor function, walking capacity, respiratory function, or muscle strength).
- B. The requested medication will be taken in combination with Opfolda (miglustat).

Pombiliti 6204-A SGM P2024.docx

© 2024 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.




Reference	
number(s)	
6204-A	•

### V. REFERENCES

1. Pombiliti [package insert]. Philadelphia, PA: Amicus Therapeutics US, LLC; September 2023.

Pombiliti 6204-A SGM P2024.docx

© 2024 CVS Caremark. All rights reserved.



This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written